...
首页> 外文期刊>The American heart journal >Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction
【24h】

Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction

机译:入院时的多种生物标志物与接受急性ST段抬高型心肌梗死的初次经皮冠状动脉介入治疗的患者的血管造影,心电图和影像学心血管指标相关

获取原文
获取原文并翻译 | 示例

摘要

Background: The multimarker risk score, based on estimated glomerular filtration rate, glucose, and N-terminal probrain natriuretic peptide (NT-proBNP), has been shown to predict mortality in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). In this study, we investigated the relation between the multimarker risk score and cardiovascular mechanistic markers of outcomes in STEMI patients undergoing PPCI. Methods: Complete biomarkers were available in 197 patients with STEMI. Angiographic Thrombolysis In Myocardial Infarction flow grade and myocardial blush grade at the end of the PPCI, electrocardiographic ST-segment resolution (STR) at the time of last contrast injection and 240 minutes after last contrast, and cardiac magnetic resonance (CMR) left ventricular ejection fraction (LVEF) and infarct size at 4 to 6 months after the index event were available. Results: In linear regression models, higher multimarker scores were associated with worse angiographic (P <.01 for both outcomes), electrocardiographic (P <.001 for the association with STR at last contrast, and P <.01 for STR at 240 minutes), and CMR outcomes (P <.01 for both). Conlusions: The multimarker risk score is associated with angiographic, electrocardiographic, and CMR mechanistic markers of outcomes. These data support the ability of the multimarker risk score to identify patients at high risk for suboptimal reperfusion and CMR outcomes and may aid in the early triage of patients who stand to benefit most of adjuvant treatments in STEMI.
机译:背景:基于估计的肾小球滤过率,葡萄糖和N末端脑钠肽(NT-proBNP)的多标志物风险评分已显示出可以预测原发性经皮ST段抬高型心肌梗死(STEMI)患者的死亡率冠状动脉介入治疗(PPCI)。在这项研究中,我们调查了在接受PPCI的STEMI患者中多标记危险评分与心血管机制预后的关系。方法:197例STEMI患者可使用完整的生物标志物。 PPCI结束时的心肌梗死的血管造影溶栓程度,心肌腮红分级,最后一次造影剂注射时和最后一次造影剂后240分钟的心电图ST段分辨率(STR),以及左室射血的心脏磁共振(CMR)指数事件发生后4到6个月的血流分数(LVEF)和梗死面积可用。结果:在线性回归模型中,较高的多标记评分与较差的血管造影(两种结果的P <.01),心电图(与最后一次对比的STR相关的P <.001和在240分钟的STR的P <.01相关) )和CMR结果(两者均P <.01)。结论:多标志物风险评分与血管造影,心电图和CMR机制标志物相关。这些数据支持多标志物风险评分能力,可以识别处于次最佳再灌注和CMR结果高风险中的患者,并且可以帮助能够从STEMI中受益于大多数辅助治疗的患者早期分流。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号